New hope in fight against brain cancer: major trial tests targeted drug

This study is testing if adding a new targeted drug, vorasidenib, to the usual treatment (radiation and chemotherapy) works better for people with a specific type of newly diagnosed brain tumor called grade 3 astrocytoma. About 408 patients will receive either the new drug combination or a placebo with standard care to see which keeps the cancer from growing longer. The goal is to improve survival and quality of life by better controlling the disease.